ASCO 2026 Conference Intelligence

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26 May 29 - June 2 | Chicago Which trial are you watching most closely? 🌟 PLENARY GAME-CHANGERS 1️⃣ PROTEUS Perioperative apalutamide + ADT in high-risk localized prostate cancer 2️⃣ LIBRETTO-432 Adjuvant selpercatinib in RET+ NSCLC https://t.co/vABvne9Yft

🫁 THE 10 MOST IMPORTANT LUNG CANCER TRIALS OF #ASCO26 🎯 TARGETED THERAPY MOVES EARLIER 1️⃣ LIBRETTO-432 (LBA3) Adjuvant selpercatinib in resected RET+ NSCLC Precision medicine officially enters curative-intent RET disease. 2️⃣ NeoADAURA Neoadjuvant osimertinib ± https://t.co/EE74GQQjzG https://t.co/wsAdevStyx

< 3 wks to #ASCO26, here is a📝 of 🔑abstracts for general onc that could guide our SoC! - #RASolute302 - #EPISODE3 - #LIBRETTO432 - #HARMONi6 - #PROTEUS - #EV302 - #SARC041 - #persevERA - #origAMI5 - #MajesTEC9 & #SUCCESOR2 #OncTwitter @ASCO @OncoAlert @OncUpdates https://t.co/trnsHuvxhh

🆙 #ASCO26 #LCSM Plenary Session 🔥LIBRETTO-432: Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC 🎙️Dr. Jonathan W. Goldman 🔢LBA3 ☑️NCT04819100 🔗 https://t.co/GSrrTlVitL @OncoAlert @Larvol @ASCO https://t.co/ePA1n6FNLw https://t.co/BU8415bIlm

@ASCO #ASCO26 Plenary Session Abstracts were just released and like a parent only seeing their kid at the stage- I’m only seeing the 2 thoracic 🫁abstracts and the RAS (ON) for pancreatic cancer drug that we need for lung cancer. #lcsm ▶️ #LIBRETTO432 Adj #selpercatinib 🫁 ▶️ https://t.co/qZsVqmAmla

The results are in! From oncogene-driven NSCLC to new data in SCLC, here is what your colleagues will be watching at the #ASCO26 Annual Meeting: 🔥 Top Focus Areas: • Oncogene-driven NSCLC • 1L Squamous NSCLC 🚀 Key Abstracts to Watch: • LBA3: LIBRETTO-432 results for

Watching LIBRETTO-432 and HARMONi-6 closely. Good trials, but calling them practice-changing for UK patients is fantasy while procurement and staffing are broken. https://t.co/6UeA8VhlZp

Original Article: First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer (Beamion LUNG-1 trial) https://t.co/VgM9kRUNTa Editorial: 𝘌𝘎𝘍𝘙’s Poor Sibling https://t.co/Nei4F2FRu9 #Oncology https://t.co/LGfmF9KWUO

This is the treatment algorithm we have used to drive our 🗣️ with @lungoncdoc on targeted options in 1L for metastatic NSCLC! ✅ Zongertinib recently added ✅ Data around front line when you have multiple options ✅ Role of Re-testing #lcsm #OncTwitter @OncoAlert @OncUpdates https://t.co/k3Bf3SXVgp https://t.co/c2q1e8HvyI

Beamion LUNG-1 trial: Until recently, no first-line targeted treatment options were available for HER2-mutant non–small-cell lung cancer. Research evaluating zongertinib is summarized in a new Quick Take video. https://t.co/LAVElpvitp https://t.co/a4IwfEOIum

New in the April 30, 2026, issue of NEJM: First-Line Zongertinib in Advanced HER2-Mutant NSCLC (Beamion LUNG-1 trial) https://t.co/VgM9kRUNTa An Intervention to Improve Maternal Infection Outcomes (APT-Sepsis trial) https://t.co/2Rt6qT01bR Mim8 in Hemophilia A with or without https://t.co/v5DQBkyWHp

First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer https://t.co/hek4yk2UUN https://t.co/3xRfrxhAzI

First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer https://t.co/wCTYPWUA4L https://t.co/IUqXTT55Jl

🫁 First-line results for HER2-mutant #NSCLC: Zongertinib: • 76% ORR • Durable responses (~15 months) • Activity in brain mets ➡️ Selective HER2 inhibition may help balance efficacy + toxicity. 🔸 John Heymach, MD, PhD of @UTMDAnderson | @NEJM https://t.co/it91AmzBGr https://t.co/DsOMI6zf9t

The #FDA granted accelerated approval to zongertinib, a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous #NSCLC whose tumors have HER2 TKD activating mutations. https://t.co/RsIUYI6vQ3 https://t.co/bVDaG6Ckif

🇨🇳 Boehringer Ingelheim’s Hernexeos (zongertinib) wins approval in China for a new indication: 1L monotherapy for adults with unresectable locally advanced or metastatic NSCLC harboring HER2 (ERBB2) activating kinase‑domain mutations — previously granted priority review.

THEME 1: What is the optimal sequencing strategy for patients with #HER2 mutations? We have 1L zongertinib approval, but should we intensify with HER2 TKI + platinum / pem, HER2 TKI + HER2 ADC, or something else (like a modified BRIGHTSTAR) approach? What about non-TKD HER2? https://t.co/sjujUcmEp0

The NMPA Grants Conditional Approval to @BoehringerTR's Hernexeos for 1L HER2-Mutant NSCLC #boehringeringelheim #hernexeos #zongertinib #bi1810631 #nsclc #beamionlung1 #regulatory #nmpa #conditionalapproval #beamionlung2 #beamionlung3 https://t.co/onePRsrQFC

First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer in @NEJM https://t.co/wCTYPWUA4L https://t.co/1JVD8qHOWj

Remarkable is an understatement! #ASCO26 7-yr update (Abstract 8502, CROWN): 1L lorlatinib in advanced ALK+ NSCLC — median PFS STILL not reached at 7 years, the longest ever in advanced NSCLC. 7-yr PFS 55% vs 3% for crizotinib. Clear 24 mo and you have a 79% chance of being PFS https://t.co/FdjyMSzkIi

🧵 CROWN 7-Year Update: Lorlatinib in 1L ALK+ NSCLC: the longest PFS ever reported in advanced NSCLC keeps getting longer!!! #ASCO26 🫁 Abstracts! Presenter: @TonyMok9 Key takeaways: 👇 @ALKPositiveinc 1) 1/ 📈 Median PFS STILL not reached at 7 years. • 7-yr PFS rate: 55% https://t.co/SoInsv7wwc

🆙 #ASCO26 #LCSM Oral Abstract Session 🔥CROWN: Lorlatinib vs Crizotinib as First-Line Treatment for Advanced ALK+ NSCLC: 7-Year Update 🎙️ @TonyMok9 🔢8502 ☑️NCT03052608 🔗 https://t.co/GgYuAT6KsN @OncoAlert @Larvol @ASCO https://t.co/CVByWraVH8 https://t.co/JcbFKPl6DZ

🆙 #ASCO26 #LCSM Oral 🔥CROWN: Lorlatinib vs Crizotinib in ALK+ NSCLC ✅mPFS NR (HR 0.19) ✅7-yr PFS 55% vs 3% ✅44% still on lorlatinib at 7y ✅No new IC progression after 30m 🎙️ @TonyMok9 🔢8502 ☑️NCT03052608 🔗 https://t.co/GgYuAT7iil @OncoAlert @Larvol @ASCO @ALKPositiveinc https://t.co/UhlKhW6F54 https://t.co/D5Oj4bFXZY

Looks like pCR was named after CROWN- the CROWN jewel of ALK TKIs and path responses alike! But as a real CROWN princess- while lorla is amazing it also requires some extra pampering! https://t.co/MHp0rURjte https://t.co/2hHXXURzX9

First pivotal sacituzumab-TMT win for $MRK https://t.co/PnTm6idjlE https://t.co/zjAamEPcPo

This one needs a thread because there are a lot of caveats: First-in-class at #ASCO26 (Abstract 8506, OptiTROP-Lung05): the first phase 3 to show an ADC + pembro beats pembro in 1L PD-L1+ NSCLC. Sac-TMT (TROP2 ADC) + pembro vs pembro: PFS not reached vs 5.7 mo, HR 0.35, ORR 70% https://t.co/ThkTczAllD

🆙 #ASCO26 #LCSM Oral 🔥OptiTROP-Lung05: 1L Sac-TMT + Pembro vs Pembro in PD-L1+ NSCLC ✅mPFS NR vs 5.7m (HR 0.35) ✅ORR 70.2% vs 42.0% ✅OS HR 0.55 (95%CI 0.36-0.85, immature) 🎙️Dr. Caicun Zhou 🔢8506 ☑️NCT06448312 🔗 https://t.co/t76ae3dVDU @OncoAlert @Larvol @ASCO https://t.co/eMpVRm2UrU https://t.co/dSbMUQojWS

Merck's ADC sac-TMT posts its first global Phase 3 win — earlier than expected. https://t.co/Dla0xwqHVj

ASCO 2026 abstracts go live at 5pm ET today. The story the market is underpricing: Chinese biotech has moved from pipeline storytelling to head-to-head data. Kelun-Biotech alone landed 3 oral presentations — including the Phase 3 OptiTROP-Lung05 (sac-TMT + pembrolizumab, 1L

🧵🧠 A BiTE that crosses the blood-brain barrier? Tarlatamab just showed intracranial responses in SCLC brain mets — one of the hardest-to-treat populations in oncology!!! @ASCO26: DeLLphi-304: Intracranial efficacy, Presented by @g_mountzios #SCLC @SclcSMASHERS https://t.co/VFcax1LKbS

With #ASCO26 just around the corner, it is my great pleasure to present in the oral abstract session, alongside prominent colleagues and chairs, the intracranial efficacy data of #tarlatamab from #DeLLphi-304 trial, the first data on CNS efficacy of a T-cell engager in #SCLC. https://t.co/tBoQcy4JaT

Great to see prospective intracranial activity with tarlatamab in SCLC brain mets. I’ve been using it in selected patients with asymptomatic CNS disease and, at times, deferring upfront radiation. Encouraging to finally see supporting data from DeLLphi-304. #SCLC #ASCO26 https://t.co/V3015i24k6

🆙 #ASCO26 #LCSM Oral Abstract Session 🔥DeLLphi-304: Intracranial Efficacy of Tarlatamab vs Chemotherapy as 2L Treatment for SCLC 🎙️ @g_mountzios 🔢8006 ☑️NCT05740566 🔗 https://t.co/8iTfUt2wCF @OncoAlert @Larvol @ASCO https://t.co/8SvE3wkT71 https://t.co/LGlDkEhy4w

🆙 #ASCO26 #LCSM Oral 🔥DeLLphi-304: Tarlatamab vs CT in 2L SCLC with BM ✅CNS PFS 6.5 vs 4.2mo (HR 0.40) ✅CNS CR 15% vs 5%; CNS shrinkage ≥30%: 56% vs 38% ✅mOS in BM pts: 13.9 vs 6.8mo 🎙️ @g_mountzios 🔢8006 ☑️NCT05740566 🔗 https://t.co/8iTfUt34sd @OncoAlert @Larvol @ASCO https://t.co/XKHMTOP3wN https://t.co/Mgw3Fl7DKx

Pleasant Surprise from #ASCO26 Abstract 8002 (LORIN): neoadjuvant lorlatinib in stage III ALK+ NSCLC hits a pCR of 46.9% and MPR of 81.3% — pathologic responses we rarely see with neoadjuvant TKIs. 75% of initially unresectable pts converted to surgery. Targeted neoadj earning https://t.co/sO30ZxYAZ7

📝 #ASCO26 Abstr 8002 | LORIN The prospective phase 2 study evaluating neoadjuvant lorlatinib for stage III ALK+ NSCLC. All patients had stage III disease, yet the results were striking: ✅ pCR: 47% ✅ MPR: 81.3% pCR nearly 50% in stage III… seriously? 🤯 🤔 What makes ALK

🆙 #ASCO26 #LCSM Oral 🔥LORIN: Neoadj Lorlatinib in Stage III ALK+ NSCLC ✅ORR 83.7%, pCR 46.9%, MPR 81.3% ✅75% unresectable → conversion surgery ✅1y EFS 97.1% 🎙️Dr. Chao Zhang 🔢8002 ☑️NCT05740943 🔗 https://t.co/2OWLWDewMH @OncoAlert @Larvol @ASCO @ALKPositiveinc https://t.co/3EXHCB4IFx https://t.co/4s53cT4Ch5

🆕 #ASCO25 🆙 ☑️#LCSM Rapid Oral, LocReg/SCLC 🔥CheckMate 77T: Perioperative nivolumab (NIVO) vs placebo in pts with resectable NSCLC 🎙️ Dr. Mariano Provencio Pulla 🎯Premature OS HR 0.85 overall, 0.60 lung cancer specific @OncoAlert @ASCO @Larvol https://t.co/1adCy9xUmf https://t.co/swmYoyITxM

Alright. Abstracts are out. This is one of the studies I really wanted to see… and I’m disappointed. TRITON IA (T+D+CT vs P+CT, STK11/KEAP1/KRAS NSQ mNSCLC): only ORR + DoR reported, PFS still blinded. ORR within noise (39% vs 35%) but durability intriguing (100% vs 58% in https://t.co/zo6RDG5BuI

And, as we are talking RET, The new kid on the block: LUNBOTINIB. We have the trial open @SylvesterCancer in Miami. Impressive #ASCO26 data (Abstract 8505): lunbotinib, a next-gen brain-penetrant RET inhibitor, posts ORR 87% in PRE-TREATED RET+ NSCLC (mPFS 27.5 mo) & 81% https://t.co/QVyKwgC5ao

🆙 #ASCO26 #LCSM Oral 🔥Lunbotinib: Phase 2 in RET Fusion+ NSCLC ✅Pre-tx: ORR 87.1%, mPFS 27.5m ✅TKI-naïve: ORR 81.3%, mPFS NR ✅IC-ORR 82.6%/75.0% (pre-tx/naïve) 🎙️Dr. Qing Zhou 🔢8505 ☑️NCT05265091 🔗 https://t.co/M79VnLrtJb @OncoAlert @Larvol @ASCO @RetRenegades https://t.co/nsgwccJUji https://t.co/PWLWfzaGp8

🆙 #ASCO26 #LCSM Oral Abstract Session 🔥CHRYSALIS-2: Overall Survival of First-Line Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC 🎙️Dr. Joel W. Neal 🔢8501 ☑️NCT04077463 🔗 https://t.co/Yj4jbQrhIo @OncoAlert @Larvol @ASCO https://t.co/3wPzAWxWmd https://t.co/1zIIUdhlv1

🆙 #ASCO26 #LCSM Oral 🔥CHRYSALIS-2: 1L Ami-Laz in Atypical EGFR-Mutated Advanced NSCLC ✅mOS 41.0m ✅3-yr OS 55%, 4-yr OS 46% ✅20% still on 1L tx (up to 4.4yr) 🎙️ @JoelNealMD 🔢8501 ☑️NCT04077463 🔗 https://t.co/Yj4jbQrPxW @OncoAlert @Larvol @ASCO @EGFRResisters @Exon20Group https://t.co/d9E1DwQrmA https://t.co/Xm2RdZmeRx

Significant #ASCO26 update (Abstract 8501, CHRYSALIS-2): 1L amivantamab + lazertinib in atypical EGFR+ NSCLC delivers median OS of 41 months — nearly double afatinib's ~19.4 mo in this hard-to-treat subgroup. 46% alive at 4 yrs, 20% still on 1L therapy. Atypical EGFR finally https://t.co/dTfWspXfmp

Very helpful overview of ivonescimab at #RomeLung26 from @GautschiOliver - eagerly awaiting OS results from HARMONi-6 at #ASCO26. https://t.co/dGrAb4cD53

🆙 #ASCO26 #LCSM Plenary Session 🔥HARMONi-6: Ivonescimab Plus Chemotherapy vs Tislelizumab Plus Chemotherapy in Previously Untreated Advanced Squamous NSCLC: OS Results 🎙️Dr. Shun Lu 🔢LBA4 ☑️NCT05840016 🔗 https://t.co/GKbAmcZHEw @OncoAlert @Larvol @ASCO https://t.co/SRA8Lob4V6 https://t.co/X3tEmRrJQE

🆙 #ASCO26 #LCSM Oral 🔥AcceleRET-Lung: 1L Pralsetinib vs SOC in RET Fusion+ NSCLC ✅mPFS 18.7 vs 9.0m ✅ORR 65.5% vs 41.6% ✅mDOR 20.6 vs 9.7m 🎙️ @DrSanjayPopat 🔢8504 ☑️NCT04222972 🔗 https://t.co/gTg2nPXgqk @OncoAlert @Larvol @ASCO @RetRenegades https://t.co/jPgAz8M0qr https://t.co/jpgd7fBJWR

This is one is personal as I presented the five-year follow-up of ARROS last year: Phase 3 confirmation at #ASCO26 (Abstract 8504, AcceleRET-Lung): 1L pralsetinib doubles PFS vs chemo in RET+ NSCLC (18.7 vs 9.0 mo, p=0.003), ORR 66% vs 42%, DOR 20.6 vs 9.7 mo. RET-directed 1L https://t.co/B3nYlKSYte

NOW ENROLLING👉 SUNRAY-01, a Ph3 trial investigating a dual approach to treat advanced, high (≥50%) PD-L1 #KRAS G12C-mutant NSCLC. Find patient requirements & detailed trial info here: https://t.co/wWLj8Tv2FL #LCSM #NSCLC #ClinicalTrials https://t.co/BqfTUO1N4c

🆙 #ASCO26 #LCSM Poster Session 🔥SUNRAY-01/LOXO-RAS-20001: 1L Olomorasib + Pembrolizumab in KRAS G12C–Mutant Advanced NSCLC with PD-L1 0-49% 🎙️Dr. Bryan Chan 🔢8628 ☑️NCT04956640, NCT06119581 🔗 https://t.co/Gl53r04g8d @OncoAlert @Larvol @ASCO @KRASKickers https://t.co/LYzDqT0YED

🆙 #ASCO26 #LCSM Poster Session 🔥SUNRAY-01/LOXO-RAS-20001: 1L Olomorasib + Pembrolizumab +/- Chemotherapy in KRAS G12C–Mutant NSCLC 🎙️Dr. Timothy F. Burns 🔢8570 ☑️NCT04956640 🔗 https://t.co/UdmQfHlJCv @OncoAlert @Larvol @ASCO @KRASKickers https://t.co/BlpTbL6xNI

🩺SUNRAY 01 Part A | KRAS NSCLC Phase 3 Trial | Now Enrolling A phase 3 trial evaluating a targeted, PD 1 inhibitor–based approach in treatment naïve KRAS G12C mutant NSCLC. 🔗 Trial details & enrollment info: https://t.co/DzfMCLDaa2 #NSCLC #ClinicalTrials #LCSM #KRASG12C https://t.co/We5WCsOkdB

🆙 #ASCO26 #LCSM Oral 🔥ALKOVE-1: Neladalkib in ALK+ NSCLC ✅preTKI (91% prior lorlatinib): ORR 31% ✅TKI-naïve: ORR 86%, 12mo DOR rate 91% ✅IC-ORR 78%, no CNS progression 🎙️ @JessicaJLinMD 🔢8503 ☑️NCT05384626 🔗 https://t.co/mEe8ZerwcU @OncoAlert @Larvol @ASCO @ALKPositiveinc https://t.co/PguNa1x9gt https://t.co/lyjIlbGv99

Notable #ASCO26 data (Abstract 8503, ALKOVE-1): neladalkib, a next-gen ALK TKI built to beat resistance, shows real activity AFTER lorlatinib — ORR 26% post-lorla, 48% after a single 2nd-gen TKI, with CNS responses & activity vs G1202R. TKI-naïve ORR 86%. A genuine https://t.co/tR5pWAY0zE

Dr. Andrea Ardizzoni discusses maintenance therapy for SCLC at #RomeLung26. Very logical approach but many historic failures for continuous and switch maintenance. Phase III IMforte with maintenance lurbinectedin was the first to improve PFS and OS and a new standard. https://t.co/FMAEPnG4Xf

@OncUpdates @sands_jacob @OncBrothers SCLC treatment has quietly had more movement in the last 2 years than in the prior two decades. The ADRIATIC consolidation data was practice changing and now with tarlatamab in 2L+ we finally have something beyond topotecan. Would be great to see how lurbinectedin maintenance

🆙 #ASCO26 #LCSM Oral 🔥ALCHEMIST (A081105): Adj Erlotinib vs Obs in Resected EGFRm NSCLC ✅OS HR 0.89 (95%CI 0.59-1.34) ✅DFS HR 0.74 (95%CI 0.55-1.01) 🎙️Dr. Ramaswamy Govindan 🔢8001 ☑️NCT02193282 🔗 https://t.co/4KZutaZBj0 @OncoAlert @Larvol @ASCO @EGFRResisters https://t.co/zmfSqsusgx https://t.co/2Ztp4pPqSu

🆙 #ASCO26 #LCSM Oral 🔥ALCHEMIST (EA5142): Adj Nivo after Surgery + Chemo in Resected NSCLC ✅DFS HR 0.97 (95%CI 0.81-1.17) ✅PD-L1 ≥50%: DFS HR 0.86 (95%CI 0.59-1.25) 🎙️ @ChaftJamie 🔢8000 ☑️NCT02595944 🔗 https://t.co/0YSU8XAmyJ @OncoAlert @Larvol @ASCO https://t.co/j0uGrieGSw https://t.co/JYqBoUQEGS

Our research at #ASCO26: -Late-breaking update in Merkel cell carcinoma (STAMP/EA6174) -Trial results in glioblastoma (EAF151) & lung cancer (EA5142 ALCHEMIST) -Emerging approaches in precision oncology - AI-driven insights (TAILORx) -ctDNA (NCI-MATCH) https://t.co/EnOS90XlMQ

The lesson isn't "these drugs don't work" — it's sequencing & timing. Erlotinib's DFS-without-OS echoes ADAURA's central question; nivo's miss reinforces that IO's adjuvant value lives in the peri-op (neoadj±adj) design, not bolted on after chemo. The control arm of 2026 is a

🚨 New edition of The OncoAlert Newsletter is live — and this one is packed. REGISTER TO GET IT👉 https://t.co/gspVIddsef or https://t.co/d9YuqYt6MU Here's what's inside 👇 🧬 NEJM SPOTLIGHT — Daraxonrasib in RAS-mutant pancreatic cancer: 35% ORR, 8.5-mo PFS in 2L PDAC. RAS https://t.co/14HNKsNNyd

Daraxonrasib phase 3 (RASolute 302) data to be presented at #ASCO26 plenary session on May 31st. https://t.co/H7XyO8quIV

#ASCO26 is <4 weeks away! @ASCO Here are the #GI oncology oral abstracts I’m most excited about 👇 ➡️Notable phase 3s: PDAC: RASolute302 ⭐️ HCC: EMERALD-3 & IMBRAVE251 EGC: ATTRACTION 6 & BL-B01D1-305 CC: FIGHT-302 CRC: PUMP (HAI), EPISODE-III (ASA) - HER2+: Tras rezetecan https://t.co/JVuYKa9SHf

For years, GI oncology meetings felt defined by incremental progress & cautious optimism. #ASCO26 feels different. The phase 3 RASolute 302 data with @RevMedicines daraxonrasib in 2L #pancreaticcancer is a true milestone moment for RAS-targeted therapy. And this is just the

@oncodaily @OncoDailyGI @OncBrothers @brunolarvol @MSK_DeptOfMed @MSKCancerCenter @lustgartenfdn @NatureMedicine @CD_AACR @CpcrMsk @GiOncNow 7/n This is not the finish line🏁 RASolute 302, 303, 304 and more. Deeply grateful to the patients 💜, families👨‍👩‍👧‍👦, investigators👨‍⚕️🩺, research teams🏥 and collaborators who made this work possible. The final result of RASolute 302, registrational randomized phase 3 trial https://t.co/nVyORkUHek

Phase 1/2 data for our RAS(ON) multi-selective inhibitor published in @NEJM. Findings contributed to the scientific and clinical rationale for Phase 3 RASolute 302 trial in metastatic RAS mutant pancreatic cancer. More: https://t.co/hkM1z0skXl https://t.co/AqFc4ZcAfu

Phase 1/2 data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/qjRucVNcCs

Daraxonrasib (RASolute 302 trial) just posted a .40 HR and was hailed a miracle. What happens when the $SLS REGAL trial produces even better results, with a first of its kind peptide therapy that can be applied to many other WT1 cancer targets? Billions. Lots of billions!!! https://t.co/Jwl0cTIOXm

➕Plenary: Rasolute 302, daraxonrasib phase III https://t.co/ebhNTu7DtU

🩺 THE 10 MOST IMPORTANT GI CANCER TRIALS OF #ASCO26 🌟 PLENARY & PRACTICE-CHANGERS 1️⃣ RASolute 302 (LBA5) Daraxonrasib (RMC-6236) vs chemotherapy in metastatic pancreatic cancer Can RAS finally become druggable in pancreatic cancer? 2️⃣ CIRCULATE (LBA3500) ctDNA-guided https://t.co/waiLddBHrv https://t.co/wsAdevStyx

🧬 Which upper GI abstracts should clinicians watch at #ASCO2026? Dr. @Erman_Akkus @AnkaraUni previews major studies including RASolute-302, DESTINY-Gastric, and HERIZON across pancreatic, gastric, biliary, and HCC care. 🎥 Watch on #Vumedi: https://t.co/HgsZB3O8lN https://t.co/WnIlYAxmgs

🚨ASCO 2026 Scouting Report 🚨 👀 VIDEO: 5-minute breakdown on key watch points + clinical context 👇 👉https://t.co/Gpy5GbxUiW The 3 Plenary trials that might change your practice: ✅RASolute 302 – daraxonrasib nearly doubles OS (13.2 vs 6.7 mo, HR 0.40) in 2L pancreatic https://t.co/JkQhchtSTb

@UGrewalMD @TheGutOncLab @NEJM Efficacy data interestingly seem very similar to what’s been released from RASolute 302

$RVMD isn’t just leading the RAS race; it’s building a fortress. 🏰 ​With shares holding steady at the $150 level, the market is finally pricing in the gravity of the RASolute 302 data. A Hazard Ratio of 0.40 (60% reduction in risk of death) in pancreatic cancer is nothing short

🔎 FDA News: The #FDA has authorized expanded access to daraxonrasib for metastatic #PancreaticCancer, after phase 3 results show major survival gains over chemotherapy and manageable safety. Read more: https://t.co/wG31FzGum2 #GICancers #PDAC #FDANews

Pancreatic cancer may be entering a new era. Daraxonrasib receives rapid FDA expanded access in metastatic PDAC (approved in 2 days). RASolute 302: * OS: 13.2 vs 6.7 months * 60% reduction in risk of death Key questions: Will RASolute 303 reproduce this in the first-line

Celebrating RASolute302 Results of Daraxonrasib in Pancreatic Cancer - Shubham Pant @DrShubhamPant @MDAndersonNews https://t.co/vsZNKBYb90 https://t.co/g2OMtbFrYI

Revolution Medicines to discuss data from Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma $RVMD, #RevolutionMedicines, #RevMed https://t.co/rKwXoNTqHs

🚨@ASCO GI Abstracts to Watch 👀 ⭐️RASolute 302: daraxonrasib vs chemo in mPDAC ⭐️HERIZON-GEA-01:PD-L1 subgroup data ⭐️BREAKWATER +SWOG S2107 : IO + chemo backbone in BRAF V600E mCRC ⭐️CIRCULATE: ctDNA-guided adjuvant in stage II colon cancer #OncTwitter https://t.co/oRM2ert8E9

📝 The phase 1/2 data of daraxonrasib in #PancreaticCancer have been published in @NEJM. These data led to the phase 3 RASolute 302 trial which supported the FDA's recent allowance of early access to the RAS inhibitor. Read more: https://t.co/hdwXMVxr5s #PDAC #GICancers

@DrRishabhOnco RASolute-302… all day erryday

Daraxonrasib Phase 3 Data Marks a Momentous Occasion for the Field - Anirban Maitra @Aiims1742 https://t.co/eTqdZpCkcX https://t.co/WXD1ERbAn2

4/4 Take-home message. Daraxonrasib showed meaningful activity across common KRAS variants including G12D, G12V and G12R. The key lesson: High efficacy comes at the cost of frequent dose optimisation rather than discontinuation. Now all eyes on RASolute-302. 🔬

Standard of care in 2nd line metastatic pancreatic cancer may have just been rewritten. May 6th NEJM published Phase 1/2 daraxonrasib data. The Phase 3 RASolute 302 reported HR 0.40 for OS, 13.2 vs 6.7 months, p<0.0001. One of the largest OS hazard ratios for mutant KRAS PDAC. https://t.co/9SG1DHjf7o

Phase 3 RASolute 302 results — already toplined: Daraxonrasib vs standard chemotherapy (2nd line PDAC): → Median OS: 13.2 months vs 6.7 months → Hazard ratio: 0.40 → p < 0.0001 That's nearly DOUBLE the survival. An HR of 0.40 in pancreatic cancer is almost unheard of.

Phase I data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/15HOeWlm0Q

@OncUpdates @ASCO RASolute 302 is the readout that could actually change PDAC frontline if the OS hazard holds up across G12D and G12V subgroups. HERIZON-GEA PD-L1 subgroup will tell us whether HER2-low gastric is sequencable.

Phase I data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/uwUuuER8Ak

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

3 macro indicators from a single week for oncology capital allocation over the next decade. 1. Daraxonrasib, Phase 3 RASolute 302 2. Vepdegestrant, FDA Approved , May 1 3. BioNTech 22% of workforce cut a structural shift in biopharma strategy rather than a standard news cycle.

Abstract Titles #ASCO26 Rapid oral, upper GI ◾️Ph2 savolitinib in MET-amp GEA ◾️PD-L1 subgroup analysis from HERIZON-GEA-01 ◾️Ph3 neoadjuvant/adjuvant serplulimab vs placebo combined with chemo for PD-L1 positive GC @ASCO @OncoAlert

#ASCO26 Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: PD-L1 subgroup analysis from HERIZON-GEA-01 $ZYME $JAZZ $RHHBY https://t.co/Q5tkPBskD6

#ASCO26 abstr 4010 PD-L1 subgroup from Ph3 HERIZON-GEA-01 @ASCO @OncoAlert https://t.co/1RdjgYQmhr

#ASCO26 Characterization and management of gastrointestinal adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: Analysis from HERIZON-GEA-01 $ZYME $JAZZ $RHHBY https://t.co/cydoHSnnT4

💥 @US_FDA has granted priority review to zanidatamab-based regimens in first-line HER2+ GEA based on data from the phase 3 HERIZON-GEA-01 trial. Full details 📈: https://t.co/41mtHbzq6a #esocsm #oncology

The @US_FDA has granted priority review to zanidatamab-based regimens in first-line HER2+ gastric cancer, GEJ cancer, and GEA. #esocsm #oncology https://t.co/ZM3jcGOKOe

📰 News based on results from the phase 3 HERIZON-GEA-01 trial: Tislelizumab, zanidatamab, and chemo received priority review for first-line unresectable advanced or metastatic HER2+ gastric, GEJ, or esophageal adenocarcinoma. ➡️ https://t.co/k34LknkaxQ #GIcancer https://t.co/HCZmhvh3Kg

ICYMI: The #FDA granted priority review to #zanidatamab regimens for 1L HER2+ gastric/GEJ/GEA. PDUFA action date: August 25, 2026 Read more: https://t.co/v7a2Mtj4wI

🔥Hot off the press! #ASCO26 abstract release: Phase 3 data from FIGHT-302 to highlight the clinical utility of first-line oral pemigatinib vs gemcitabine/cisplatin in biomarker-selected, FGFR2+ metastatic #CCA. Unpack the newly published details below! ⬇️ @ASCO @GIcancerDoc

#ASCO26 https://t.co/vN5XTT9RAP ATTRACTION-6: Nivolumab + ipilimumab + chemo vs chemo in 1L HER2-negative G/GEJ cancer Abstract #4006 Presentation: June 1, 2026 Womp. Dual-checkpoint has a home in multiple diseases: melanoma, PD-L1 negative NSCLC, MSI-H cancers, and HCC among

#ASCO26 abstr 4006 Ph3 Nivo + Ipi + chemo vs chemo in 1L HER2-neg GEA (ATTRACTION-6) ◾️OS: 15.7 vs 15.8 mo, HR 0.90, p=0.267 ◾️PFS: 8.9 vs 7.7 mo, HR 0.83 ◾️ORR: 57.9% vs 38.5% ◾️≥G3 TRAEs: 64.8% vs 42.9% 👉Nivo + Ipi + chemo did not improve OS over chemo alone. @ASCO @OncoAlert

#ASCO26 https://t.co/eHgtQitZKI Camrelizumab + rivoceranib + TACE vs TACE alone in uHCC Abstract #: 4001 Presentation: June 1, Upper GI Orals In HCC, the question is increasingly not local vs systemic, but how best to combine the two. This China-based randomized phase 3 trial

#ASCO26 abstr 4008 Ph3 Iza-bren vs chemo in 2L ESCC ◾️OS: 9.8 vs 7.2 mo, HR 0.64, p=0.0004 ◾️PFS: 4.2 vs 2.0 mo, HR 0.50, p<0.0001 ◾️ORR: 35.3% vs 13.1% 👉Met both dual primary endpoint OS & PFS!! @ASCO @OncoAlert

#ASCO26 https://t.co/mVP9EqOW0A Trastuzumab rezetecan vs SOC in chemotherapy-refractory HER2+ advanced CRC Abstract #: 3505 Presentation: May 31 CRC Oral China-based phase 3 study, and important to interpret it in that context. This is their home-grown HER2 ADC. The mental

Abstract Titles #ASCO26 Oral, CRC ◾️Ph3 Trastuzumab rezetecan vs chemo in HER2-pos CRC ◾️DFS & TTR with ctDNA-based decision for adj Tx in stage II colon cancer ◾️BREAKWATER: PFS & OS of EC + FOLFIRI in 1L BRAF V600E mCRC ◾️SWOG S2107: rPh2 EC w/ or w/o Nivo in MSS, BRAF V600E

$AZN AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 - EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) in early liver

@allisonoconn @DrHBurstein @stolaney1 @PhilipPoorvu We now have the option of giving 4 cycles of neoadjuvant T-DXd (followed by THP, DB11 regimen) or give NACT, go to surgery, and only give adjuvant T-DXd (14 cycles, DB05 regimen) for patients with high-risk RD. Only the second trial war powered for iDFS, but both are very active! https://t.co/8gYQkpYzAj

#ESMOBreast26 DESTINY-Breast11: T-DXd→THP improved favorable RCB-0/I rates across all major HER2+ EBC subgroups 👀 🔹 HR+: 78.0% vs 64.7% 🔹 HR-: 90.4% vs 81.2% 🔹 Node-negative: 80.8% vs 68.6% 🔹 Node-positive: 81.5% vs 69.8% 📌 Benefit extended beyond pCR alone 📌 Residual https://t.co/zD3kxEp8aU https://t.co/K0CzX5q93i

🚨 FDA expands the role of Enhertu in curative-intent HER2+ early breast cancer. AstraZeneca + Daiichi Sankyo’s trastuzumab deruxtecan is now approved in the US in BOTH: 🔹 Neoadjuvant setting (DESTINY-Breast11) 🔹 Adjuvant residual disease setting (DESTINY-Breast05) Key data https://t.co/6901MjMVyP

🚨 DESTINY-Breast11 LBA1 at #ESMOBreast26 Can neoadjuvant T-DXd reshape cure-intent HER2+ breast cancer? 👀 T-DXd → THP achieved deeper responses vs standard ddAC-THP, with markedly higher favorable residual cancer burden (RCB-0/I) rates across ALL subgroups. 🔹 T-DXd → THP https://t.co/RDMSMz1PAu https://t.co/hwB5ljn3wY

DESTINY-Breast11 (DB-11) – RCB Analysis T-DXd-THP significantly improves Residual Cancer Burden compared to standard ddAC-THP in high-risk HER2+ early breast cancer. Key Highlights: • RCB-0+I rate: 81.3% vs 69.1% (+12.2%) • Consistent benefit across all subgroups (HR+, HR–, https://t.co/MR1PIF8nfl

With @myESMO Breast Cancer 2026 around the corner, we asked leading AI models to identify the most anticipated trials in breast cancer, here’s their combined ranking. There's strong consensus around trials like DESTINY-Breast11, SATEEN, and TRAIN-4—highlighting continued https://t.co/chZm3F3kzf

1. DESTINY-Breast11 (Update): Ph III, NeoAdj, TDXd -> THP vs ddAC -> THP in high risk Her2+ early breast cancer - Improved residual cancer burden (81.3% vs. 69.1%) - ⬆️ pCR: 68.8% vs. 57.5% - Awaiting OS 2/7 https://t.co/6INj42pZPL https://t.co/kbOFJ9dNnJ

Ahead of @ESMO BC 2026, we asked leading AI models to identify the most anticipated oncology trials. Now, comparing those predictions to engagement on 𝕏, here’s what stood out 👇 👉 Strong alignment at the top: SATEEN and DESTINY-Breast11 were consistently identified across https://t.co/LDafFuhqwo

FDA Approval based on DESTINY-Breast11 and DESTINY-Breast05 in #BreastCancer https://t.co/9N3IlAa0fX The FDA approved fam-trastuzumab deruxtecan-nxki for two HER2-positive early-stage breast cancer indications: neoadjuvant therapy for Stage II/III disease followed by THP, and https://t.co/h5EYySZXRF

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and https://t.co/YQRtdZK629

DESTINY-Breast11: T-DXd–Based Neoadjuvant Therapy Outperforms Anthracycline-Containing Regimens in High-Risk HER2+ EBC, Delivering Higher pCR and RCB 0/1 Rates and Supporting a Shift Toward an Anthracycline-Free Standard @OncoAlert #ESMOBreast26 https://t.co/vuUL2XQInn

@myESMO Breast Cancer 2026: Pre-Conf Top Abstracts DESTINY-Breast11 | TRAIN-4 | SATEEN | HER2CLIMB-02 | PREcoopERA | PHERGain-2 | PHERGain | MIRINAE | TRAK-ER | CAPItello-291 | TROPION-Breast02 | evERA BC | SERENA-6 | INAV0120 | Saci-IO #ESMO #ESMOBC26 #ESMOBC2026 #Cancer https://t.co/i8bDLdUJH1

Top Trials to Follow on Day 1 @myESMO Breast Cancer 2026. DESTINY-Breast11 | PHERGAIN-2 | MIRINAE | TRAK-ER | PREcoopERA #ESMO #ESMOBC26 #ESMOBC2026 #Cancer #Oncology #BreastCancer #TNBC #BCSM #trastuzumab #Tdxd #pertuzumab #TDM1 #atezolizumab #giredestrant #OncologyEvents https://t.co/BDZSXX8azz

🚨 #FDA APPROVAL: The FDA has approved fam-trastuzumab deruxtecan (Enhertu) for 2 new indications in early-stage HER2+ #BreastCancer: one neoadjuvant (DESTINY-Breast11) and one adjuvant (DESTINY-Breast05) https://t.co/CqK5GUHTpg

DESTINY-Breast11 Across all subgroups, residual disease is reduced with T-DXd-THP versus ddAC-THP #esmobreast26 @OncoAlert https://t.co/kzPYxWJMST

FDA has granted two new approvals for ENHERTU (trastuzumab deruxtecan) in HER2-positive early breast cancer. 🔹 Neoadjuvant setting (DESTINY-Breast11) 🔹 Adjuvant treatment for residual disease (DESTINY-Breast05) Some remarkable findings: * pCR rate: 67.3% vs 56.3% * 53% https://t.co/3DJfmviGaY

👀 Reduced RCB was shown for neoadjuvant T-DXd followed by THP compared with ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer, according to data from the phase 3 DESTINY-Breast11 trial. Read more here ➡️: https://t.co/A3pZFtUxf2 #bcsm #oncology

An analysis of DESTINY-Breast11 showed neoadjuvant T-DXd followed by THP improved residual cancer burden vs ddAC-THP in early-stage HER2+ breast cancer @myESMO #ESMOBreast26 Read more on the latest data here: https://t.co/wSQXtmjZSP https://t.co/AUeC9ze23b

$AZN $DSNKY Daiichi Sankyo and AstraZeneca’s Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer - Approved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3

$AZN $DSNKY AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer - Approved for use before surgery based on DESTINY-Breast11 Phase III trial - Approved for use

@DrSGraff Impressive DESTINY-Breast11 results. T-DXd delivering 81% RCB-0/I rates could spare many HER2+ patients from aggressive surgery. Fewer complications, better quality of life. This is precision oncology transforming care. 🧬

🟢 $AZN — FDA Approval FDA Approval - Enhertu neoadjuvant for HER2-positive Stage II/III early breast cancer (DESTINY-Breast11) FDA approved Enhertu (trastuzumab deruxtecan) followed by THP as neoadjuvant treatment for adult patients with HER2-positive Stage II or Stage III b…

Why no #odac for $RHHBY Imvigor-011? Pdufa date May 2026, uses ctDNA to guide treatment decision in a similar way to $AZN Serena-6 study of camizestrant - which did get an odac. https://t.co/Wbva0ZJbOR

$AZN #ASCO26 EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI®(durvalumab) and IMJUDO®(tremelimumab-actl) in early liver cancer Phase III data from SERENA-6, DESTINY-Breast09 and TROPION-Breast02 span all three major subtypes of metastatic breast cancer CARES https://t.co/8cCKHgXuGa

Today’s #ODAC vote was 6-3 against recommending camizestrant based on #SERENA6. Not GI, but very relevant to all of us. The trial asked a really important question: Can we use ctDNA to detect ESR1 resistance before scans show PD, then switch endocrine therapy early? https://t.co/qeRysSs8Mj

Possible reason, on further thought: $AZN Serena-6 proposed giving treatment sooner than standard; $RHHBY Imvigor-011 proposes to eliminate it in patients who might not need it.

@AppleHelix Agreed, and I though Capitello-281 was on far shakier ground than Serena-6. FDA basically told $AZN: if you don't show a strong PFS benefit you need OS. Result: weak PSF, no OS benefit. And yet, Truqap gets the thumbs up. What do I know!

Will the FDA approve $AZN camizestrant despite the 6-3 vote adcom against Serena-6?

News from industry: SERENA6 Update in #BreastCancer Source : AstraZeneca https://t.co/MdNXkIue2L EU CHMP has recommended approval of AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor for ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations https://t.co/qvK9sNBLsJ

SERENA-6 Surveillance Data: ESR1 mutations emerge in 42% of patients on AI + CDK4/6i. One test is not enough — serial ctDNA monitoring is essential. Early detection → timely switch to camizestrant before progression. Bidard et al. • SERENA-6 #BreastCancer #ESR1 #ctDNA https://t.co/N3StLhdwXE

In this time of oral serd controversy (SERENA-6) FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer - The ASCO Post https://t.co/Kf11KqnnUB

#datoDXd FDA approved 1st line TNBC among pts who are not a candidate for immunotherapy Not 1️⃣, not 2️⃣, but now 3️⃣ approvals in #bcsm this month! #vepdegestrant #TDxd neoadj/adj #datodxD 1st L https://t.co/FXeEAWVkqE

Dato-DXd now has FDA approval for first-line TNBC👇 TROPION-Breast02 https://t.co/AyfETdQNay

T-DM1 or T-DXd after neoadjuvant therapy? Residual HER2+ disease after NAC does not automatically mean adjuvant T-DXd. 🔹 KATHERINE → any residual invasive disease qualified for T-DM1 🔹 DESTINY-Breast05 → T-DXd studied in higher-risk residual disease Key high-risk features https://t.co/t7EORh59x2

KATHERINE ≠ DESTINY-Breast05 Both addressed residual HER2+ disease after neoadjuvant therapy — but NOT the same baseline-risk population. DESTINY-Breast05 enrolled a much more modern, treatment-exposed, higher-risk cohort: • ~81% ypN+ • ~52% initially inoperable disease • https://t.co/RozmwjUBDN

DESTINY-Breast05 may redefine post-neoadjuvant HER2 escalation. In ultra-high-risk residual HER2+ disease: • T-DXd significantly outperformed T-DM1 • 3-year IDFS: 92.4% vs 83.7% • HR 0.47 → ~53% lower invasive recurrence/death • Fewer distant + CNS recurrences But: • https://t.co/AJwNs4cQhm

T-DXd + Radiation? What DESTINY-Breast05 really showed: • >50% received concurrent RT • RT pneumonitis rates were similar with T-DXd and T-DM1 • Most events were low-grade RT-related findings • Intensive CT surveillance likely increased detection • True drug-related ILD https://t.co/jYZ9ayTpRA

REDUSE (SAKK 96/12) at #ASCO26 (Abstr 1004, oral): can denosumab be de-escalated in bone-metastatic cancer without losing skeletal protection? In patients with breast cancer or CRPC and ≥3 bone metastases (n=1,380), denosumab every 12 weeks — after 4x monthly loading — was

REDUSE (SAKK 96/12) at #ASCO26 (Abstr 1004, oral): can denosumab be de-escalated in bone-metastatic cancer without losing skeletal protection? In patients with breast cancer or CRPC and ≥3 bone metastases (n=1,380), denosumab every 12 weeks — after 4 months of monthly loading —

REDUSE (SAKK 96/12) at #ASCO26 (Abstr 1004, oral): can denosumab be de-escalated in bone-metastatic cancer without losing skeletal protection? In patients with breast cancer or CRPC and ≥3 bone metastases (n=1,380), denosumab every 12 weeks — after ~3 months of monthly loading

Redefining 1L HER2+ Metastatic #BreastCancer: From CLEOPATRA to ADC-Driven Precision Strategies 🧬 Emerging evidence from DESTINY-Breast09, HER2CLIMB-05, and PATINA highlights a major evolution toward biologically tailored frontline therapy integrating: @OncoAlert #ESMOBreast26 https://t.co/j8jG0xAuNJ

1/5 New Phase III data on giredestrant (lidERA & persevERA trials) at #ASCO26 shows potential as future standard of care in HR+ breast cancer. https://t.co/KIGt8SdDBi #breastcancer #OncoTwitter #cancerresearch

Ab#4507 @ASCO #ASCO26 by @tompowles1 @shilpaonc👉https://t.co/fxlybBjl6j👉3.5 yr f/u of Ph3 EV-302 in aUC #bladdercancer👉42-month OS rate, 44% vs 24.6%; HR=0.53👉among pts w/ CR, 66% had initially PR👇 @OncoAlert @urotoday @uromigos @BladderCancerUS https://t.co/PtSntGzMpI

GU schedule by day 📆 for #ASCO26 & (among others) looking forward to 💫 1) Bladder CA: -Data on novel nectin-4 ADCs: #NEXUS01, #EXCEED + #DURAVELO2, Bulumtatug, SHR-A2102 -Updates for: #EV302, #KN905 QoL -RAD-IO TMT w/ durva  -GemFLP in bladder adenoCA https://t.co/Y199O2urSC ── 2) Kidney CA: -NonCC-RCC: cadonilimab (PD1/CTLA4 bispecific),final ph2 cabo/nivo -Updates: #KN564 ctDNA -Panitumumab-based EGFR block in SAMRCB1-deficient RMC ── 3) Prostate CA: -#PROTEUS: perioperative apalutamide (plenary!) -mCSPC: identifying docetaxel benefit analyses from CHAARTED + ENZAMET, & ADT interruption #ADREAM, PARPi #TALAPRO3, #PSMAddition, ZZ-First -mCRPC: ADC to PSMA/STEAP1, #PLUDO doce vs Lu-617, AVPC chemo-IO ── 4) Testicular CA: -SWOG S1823 microRNA in predicting active GCT -Expert session on Optimizing Tx for Pts with Poor-Risk Testicular Cancer

7-Abstract 4507: EV-302 #DrThomasPowels will provide us with an update at #ASCO26 after 3.5 years of follow-up on the survival and response durability with enfortumab vedotin + pembrolizumab vs chemotherapy in previously untreated la/mUC. @QMBCI @ASCO @OncoAlert https://t.co/bievd0jQ52

📢 Data update! #ASCO26 abstract release: Phase 3 findings from the EV-302/KEYNOTE-A39 study show the long-term benefit of enfortumab vedotin plus pembrolizumab in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Check out the newly

Excited for #ASCO26 updates in urothelial cancer! New long-term EV-302 findings continue to evaluate outcomes w EV + pembrolizumab, w intriguing analyses on patients whose responses evolved from partial to complete response over time @tompowles1 @ASCO https://t.co/hwX5FnDEAv https://t.co/UId7wPO8Rd

Ab#4502 @ASCO #ASCO26 by @DrChoueiri👉 https://t.co/SZg3hfw1wU👉ctDNA analysis from KEYNOTE-564 trial #kidneycancer👉ctDNA+ associated w/ worse DFS👉ctDNA clearance was higher in pembro arm👇@tompowles1 @OncoAlert @urotoday @kidneyCAN https://t.co/XBoQSZPpQx

KEYNOTE-564 ctDNA analysis at #ASCO26 (Abstr 4502, oral): can ctDNA detect recurrence and refine risk in adjuvant clear cell RCC? In ccRCC at increased risk post-nephrectomy (n=994; 736 evaluable at baseline), tumor-informed, WES-based ctDNA (Signatera, 16-plex and 64-plex) was

Excited for #ASCO26 oral presentations! New analyses from KEYNOTE-564 will explore how ctDNA status and ctDNA clearance relate to outcomes in RCC treated w adjuvant pembrolizumab @DrChoueiri @ASCO https://t.co/V0LOAQJQ41 https://t.co/j8tb0DkuBa

2-Abstract LBA5007: TALAPRO-3 Delving deeper into PARP inhibition in HRR altered mCSPC . @neerajaiims from @Huntsmancancer will present the phase 3 TALAPRO-3 trial at #ASCO26, evaluating talazoparib + enzalutamide vs placebo + enzalutamide in in patients with HRR-altered mCSPC. https://t.co/MiomNvUKxw

Pre-meeting prep for #ASCO26 looked different this year. 🤖 874-page proceedings PDF through an AI agent, scored by trial design, endpoint maturity, and practice impact 📊 Can't miss: 8 sessions | High interest: 10 | On my radar: 9 🎯 TALAPRO-3, RAMPART, ProstACT Global, https://t.co/3yYuF5VA0r

Trials in #ProstateCancer and #KidneyCancer featured at #ASCO26. @DrRanaMcKay @UCSanDiego joins @zklaassen_md @GACancerCenter previewing 5 #ASCO2026 #GUOncology trials, including PROTEUS, TALAPRO-3, and RaqdiCaL. From perioperative apalutamide in high-risk prostate cancer to PARP https://t.co/1k6cZU9OIs

Impact of anemia and its management on Quality of Life in #mCRPC patients treated with talazoparib + enzalutamide. Presentation by Neal Shore, MD, FACS @CURCMB. #AUA26 written coverage by @RKSayyid @UAUrology > https://t.co/3eicQoDmCd @AmerUrological @TheSTARTCenter https://t.co/PwerpRrP0P

3) Prostate CA: -#PROTEUS: perioperative apalutamide (plenary!) -mCSPC: identifying docetaxel benefit analyses from CHAARTED + ENZAMET, & ADT interruption #ADREAM, PARPi #TALAPRO3, #PSMAddition, ZZ-First -mCRPC: ADC to PSMA/STEAP1, #PLUDO doce vs Lu-617, AVPC chemo-IO

My ASCO GU 2026 watchlist 👀 ① PROTEUS ② TALAPRO-3 ③ NEXUS-01 Perioperative PC, ctDNA in RCC, next-gen ADCs… exciting year for GU oncology. #ASCOGU #ASCO2026 https://t.co/TiZfa54A93

One to watch at #ASCO26: TALAPRO-3, a Late-Breaking Oral Abstract evaluating talazoparib + enzalutamide in HRR-altered metastatic castration-sensitive prostate cancer @neerajaiims @ASCO https://t.co/ByNa4SiPOU https://t.co/lmDgHsTzCd

@FDAOncology approved atezolizumab as adjuvant Tx in resected MIBC based on ctDNA #IMVigor011 (IO-naive patients). The candidate population is shrinking due to EV-303, EV-304, NIAGARA trials data but exists @BladderCancerUS @HsiehLab @spsutkaMD @OAlhalabiMD @shilpaonc @DrOmarMian https://t.co/jb9dPE3vfM

💥 @US_FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC based on data from the phase 3 KEYNOTE-B15/EV-304 trial. Full details 📈: https://t.co/JENvanUfyo #blcsm #oncology

🚨 EV + Pembrolizumab is rapidly reshaping the perioperative bladder cancer landscape — and now raising real possibilities for bladder preservation in MIBC. KEYNOTE-905/EV-303 and KEYNOTE-B15/EV-304 demonstrated unprecedented improvements in pCR, event-free survival, and https://t.co/GTmCJwJSEz

Evaluating EV plus pembrolizumab in muscle-invasive #BladderCancer: #KEYNOTEB15 results. @MattGalsky @TischCancer joins @ERPlimackMD @FoxChaseCancer to discuss this phase III trial randomizing 808 #MIBC patients to neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab https://t.co/XgvxmG7b4o

Ab#4568 @ASCO #ASCO26 by @PGrivasMDPhD 👉https://t.co/aRRldxFUyd👉Ph2 JAVELIN Bladder Medley trial subgroup analysis in aUC#bladdercancer👉1L maintenance Avelumab+SG improved PFS vs Ave alone👉Benefit seen across metastatic sites👉@Jcensits @oncoalert @urotoday @OpenMedicineHQ https://t.co/HDC4Ev1hPm

Delayed survival benefit of enzalutamide + radium-223 in #mCRPC: a reconstructed individual patient data analysis of the PEACE-3 trial. Presentation by @YoshidaSoichiro. #AUA26 written coverage by @RKSayyid > https://t.co/1XrfwFdM5E @AmerUrological https://t.co/j9Fm91MtPG

New data from PEACE-3 presented at #AUA26 highlight the time-dependent survival kinetics of enzalutamide plus radium-223 in patients with #mCRPC. Although no early advantage was seen during active therapy, non-proportional hazards modeling revealed a delayed but profound

🔬 Belzutifan + lenvatinib may reshape post–IO care in advanced RCC. In phase III LITESPARK-011, the combo improved PFS (14.8 vs 10.7 months), ORR vs cabozantinib. ➡️ Trend toward OS benefit. 🗣️ Presented by @motzermd of @MSK_DeptOfMed at #GU26 https://t.co/PRDKdDovbo https://t.co/xtgExtwPc1

Chris Labaki (@Chrislabaki1 ) at #GU26 highlights belzutifan monotherapy & combinations in #KidneyCancer 🧬 LITESPARK-011 shows lenvatinib + belzutifan vs cabozantinib after ICI, shaping #TKI-based algorithms & combo strategies 📊 Watch: https://t.co/QXSF4pHzoB #gusm

Tian Zhang (@TiansterZhang) highlights key #GU26 data in #KidneyCancer, including LITESPARK-011 & LITESPARK-022 📊 See how these trials can impact clinical practice here: https://t.co/UoCwNAUcpG #gusm #oncology

In between #AUA26 and #ASCO26, we're looking ahead to our webinar on the new ARASEC & ARACOG clinical trial data. ✔️ Catch up in just 30 minutes ✔️ Focus on what matters for your clinical practice ✔️ Interact live with Dr. Rana McKay & Dr. Alicia Morgans Register to join us https://t.co/iGAjujH2Ga

Early #ASCO26 news: 🚹 In the phase II ARACOG trial, patients with advanced #prostatecancer treated with darolutamide experienced significantly less cognitive decline over 24 weeks compared with enzalutamide. 🗣️ To be presented by @CaPsurvivorship 🔗 https://t.co/89LLKL0v8P https://t.co/KR7TxSnAkt

One to watch at #ASCO26: preliminary Phase 3 ProstACT Global results evaluating 177Lu-rosopatamab tetraxetan plus standard of care in metastatic castration-resistant prostate cancer @PBarataMD @ASCO https://t.co/av9UWIE8Be https://t.co/9vYyb4hVE6

In preparation for the 2026 @ASCO Annual Meeting, I'll post tweetorials for the most expected data in #sarcoma. Starting with the plenary, of course - SARC041! @SARCtrials 🧵1/ Well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS) remains one of the most common,

@asco #asco26 is four weeks away. Looking forward to seeing everyone in Chicago. Eagerly awaited: Plenary Session trials PROTEUS - Perioperative apalutamide + ADT vs placebo + ADT with radical prostatectomy in high-risk localized / locally advanced prostate cancer SARC041 - https://t.co/A33pOdQV7K

The loudest plenary trial at ASCO may be one pharma did not fund. This year’s list tells a very clear story. ⭐ Daraxonrasib 13.2 vs 6.7 mo in pancreatic cancer. But then there is SARC041. A breast-cancer drug working in sarcoma. Pharma did not fund the Phase 3. NCI CTEP https://t.co/HzLK6lZB1v

@mukundiyngr Daraxonrasib is the obvious talk of the town, but wow in the SARC041 story

5/ Then came abemaciclib. Key differences versus palbociclib: • more continuous CDK4 inhibition • continuous dosing schedule • potentially greater activity in CDK4-dependent tumors This led to the phase II study to be reported by Dickson et al (SARC041)

Desmoid tumors are “benign” histologically — but clinically aggressive, painful, and difficult to control. At #ASCO2026, the Phase 3 RINGSIDE trial showed major activity with the oral γ-secretase inhibitor (GSI) varegacestat: • HR 0.16 for progression • ORR 56% vs 9% • Deep https://t.co/pcGFvua8cy

#mmsm #ASCO26 MajesTEC-9 ➡️Tec vs. PVd/Kd (1-3 prior lines of therapy) ➡️Len refractory: 80%; anti-CD38 refractory: 85% ➡️median F/U ~1.5 yrs ➡️18-mo PFS rate: 70% vs 27% ➡️improved OS with Tec vs PVd/Kd (HR: 0.60), even with >2/3 of pts getting BsAb or CAR-T as subsequent https://t.co/WzdX5QhBg3

MagnetisMM-5 press release - elra outperformed DPd in myeloma with 1+ prior line! Obviously all eyes will be on this vs MajesTEC-3 (and more pertinently, MajesTEC-9)… … but this confirms that the heyday of Dara-Pd and Isa-Pd at first relapse is rapidly coming to an end 👏 https://t.co/alzQ0578XK

#ASCO26 @ASCO abstracts are out, looking for a great meeting #mmsm @utswcancer Here are my top 5 plasma cell disorders to watch for 🧵 1⃣MajesTEC-9: RCT of teclistamab monotherapy vs PVd/Kd in RRMM: press release with PFS and OS benefit. Will allow for earlier use of single https://t.co/BiaHZKDmbs

Most important #ASCO26 myeloma abstract. Practice changing. Majestec-9 trial. PFS significantly better with Teclistmaab vs PVd/Kd (HR, 0.29; 95% CI, 0.23–0.38; P<0.0001); 18-mo PFS rate: 69.8% vs 26.9%. OS significantly better with Tec vs PVd/Kd (HR, 0.60; 95% CI, 0.43–0.83;

majesTEC-9 results posted: Tec crushed PVd/Kd for #myeloma after 1-3 prior LOT. Results relevant for US practice, as 85% of pts were anti-CD38 refractory. 18m PFS: 70% (vs 30% for pVd/Kd), w OS benefit too (HR 0.60). https://t.co/mRnJmrkoDk

🔥Hot off the press! #ASCO26 abstract release: Phase 3 MajesTEC-9 trial data with teclistamab monotherapy in patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy. @RobertoMinaMD @MassGeneralNews @harvardmed @WinshipAtEmory

@Abdallah81MD @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @oncodaily With 85% CD38 refractory in MajesTEC-9, they are very different patient population

With 85% CD38-refractory, we are seeing at least a similar (if not better) PFS with single-agent Teclistamab when compared to Cilta-cel arm of CARTITUDE-4, which had just ~25% CD38-refractory. These results, along with MajesTEC-3, challenge the dogma of “CAR T before BsAbs” in https://t.co/D5kF3Igr8X

@kansagraMD Great to see Talq become q4 week after C4-6 and pom 2mg only. Tal-DP vs Tal-D should be looked at in HRCG, EMD, and Functionally high-risk myeloma subgroups. 2yr PFS looks similar to MajesTEC-3. This could be a great option for post 2L CAR T relapse. Will wait for https://t.co/jSHlySQ8Bn

For relapsed myeloma not refractory to dara (including dara exposed but not refractory), Teclistamab plus Dara or ciltacel remain first choice. Based on Majestec-3 trial. Tec and Tec Dara and Ciltacel are all contingent on access, and whether the treatment can be administered

@HadidiSamer It would be interesting to see if pts who were CD38 non refractory (15%) had similar outcomes to those in MajesTEC-3. In other words, do we need CD38+Tec ot TEC alone is sufficient.

@OpenMedicineHQ @VincentRK MajesTEC-3 is reshaping my approach to first relapse. Tec-dara offers strong PFS without the complexity of CAR-T. 🧬

#mmsm #ASCO26 inMMyCAR, in vivo CAR-T ➡️N=6 pts, age: 61-72 yrs ➡️CRS 4/6, all G2 (relatively higher than approved CAR-T), required tocilizumab and corticosteroids ➡️no ICANS or delayed toxicity (though very limited follow up) 🛑Follow up short overall, all responded 👇 This https://t.co/0FiktoYI6q

#ASCO26 @ASCO abstracts are out, looking for a great meeting #mmsm @utswcancer Here are my top 5 plasma cell disorders to watch for 🧵 5⃣ inMMyCAR: KLN-1010 CAR-T, phase I, initially presented in #ASH25 with short follow up and low n. Updated results. https://t.co/0NrgliNoLx

#ASCO26 @ASCO abstracts are out, looking for a great meeting #mmsm @utswcancer Here are my top 5 plasma cell disorders to watch for 🧵 2⃣SUCCESSOR-2 trial: RCT of MeziKd vs Kd in RRMM: Mezi activity post BCMA failure is encouraging and hope this will allow for access to this https://t.co/HoLQPALBx4

🆕 Article in press: Five-year survival with tebentafusp in metastatic uveal melanoma 👉 https://t.co/1Pqi1595e1 https://t.co/9OGQDXwEEG

Tebentafusp doubles 5-year survival in previously untreated metastatic uveal melanoma. Paul D. Nathan, MBBS, PhD, FRCP breaks down the phase 3 CT029 data and what ctDNA response means for predicting patient benefit. Watch now: https://t.co/1TTCgHI06E #UvealMelanoma #Oncology https://t.co/7bZrnZZ9zr

$IDYA to Initiate NDA Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program. Completion Expected in 2H'26

$IDYA full results from the OptimUM-02 trial will be presented in a late-breaking presentation at #ASCO26

$IDYA As expected,late-breaking abstract for OptimUM-02 of darovasertib in 1L metastatic uveal melanoma (HLA-A2(-) patients) was not available (until Monday, 6/1). continue to see the totality of known data from the top-line (~6.9 month PFS benefit for darovasertib + crizotinib

$IDYA to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program https://t.co/9SBOWnKWQ2

$IDYA IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

$IDYA IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma More Info: https://t.co/GHGrqamvxP